{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-004199","form_type":"8-K","ticker":"OSRH","cik":"0001840425","company_name":"OSR Holdings, Inc.","filed_at":"2026-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.485272+00:00","generated_at":"2026-05-16T10:26:11.198722+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OSR Holdings subsidiary Vaximm gets binding term sheet for VXM01 license: $30M upfront, $815M milestones","bullets":["Vaximm, OSR Holdings' subsidiary, enters binding term sheet with BCM Europe for global exclusive license of VXM01.","Upfront payment of $30M (50% cash, 50% digital assets) and up to $815M in clinical, regulatory, and commercial milestones.","Definitive agreement targeted by end of May 2026, subject to fairness opinion, board review, and final documentation.","BCM Europe, the largest OSRH shareholder, will establish a fund (BCM Decentralized Science Investors I) as licensee.","VXM01 is an oral T-cell vaccination platform targeting VEGFR-2; has shown clinical activity and safety in multiple cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-004199","json":"https://secwatch.observer/filing/0001213900-26-004199.json","markdown":"https://secwatch.observer/filing/0001213900-26-004199.md","text":"https://secwatch.observer/filing/0001213900-26-004199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840425/000121390026004199/0001213900-26-004199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840425/000121390026004199/ea0272738-8k_osrhold.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:26:11.198722+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"be963ead681929ab2b2fa2896d3236767285b461","claim":"OSR Holdings, Inc. entered into Binding Term Sheet with BCM Europe AG valued at $30.0 million (comprised of $15.0 million in cash and $15.0 million in digital assets) and up to $81 (effective 2025-01-13).","evidence_excerpt":"On January 13, 2025, Vaximm AG, a wholly-owned subsidiary of OSR Holdings, Inc. (the “Company”), entered into a Binding Term Sheet (the “Term Sheet”) with BCM Europe AG (“BCME”), the largest shareholder of the Company, relating to a proposed global exclusive license of Vaximm’s VXM01 oral cancer immunotherapy platform.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840425/000121390026004199/0001213900-26-004199-index.htm","confidence":0.92,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"BCM Europe AG"},{"label":"Value","value":"$30.0 million (comprised of $15.0 million in cash and $15.0 million in digital assets) and up to $81"},{"label":"Effective","value":"2025-01-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}